The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
Hermann Einsele
• 11 Jun 2022
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on the efficacy and toxicity profile of bispecific antibodies for multiple myeloma including teclistamab and elranatamab, discussing overall response rates (ORR), cytokine release syndrome (CRS) and infections. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
